The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours

European Urology

Volumn 70, Issue 1, 2016, Pages 106-119

  Humphrey, Peter A ^a   Moch, Holger ^b   Cubilla, Antonio L ^c   Ulbright, Thomas M ^d   Reuter, Victor E ^e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSIDAD NACIONAL DE ASUNCIÓN   (Paraguay)

^d INDIANA UNIVERSITY HEALTH   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bladder; Prostate; WHO classification

Indexed keywords

ARTICLE; BLADDER DIVERTICULUM; BLADDER TUMOR; CANCER GENETICS; CANCER GRADING; CANCER RISK; GENOMICS; HUMAN; IMMUNOPHENOTYPING; INTRADUCTAL CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE TUMOR; TRANSITIONAL CELL CARCINOMA; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; WORLD HEALTH ORGANIZATION; CARCINOMA; CLASSIFICATION; GENETICS; PATHOLOGY; TUMOR INVASION;

CARCINOMA; HUMANS; IMMUNOPHENOTYPING; MALE; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; URINARY BLADDER NEOPLASMS; WORLD HEALTH ORGANIZATION;

EID: 84961221276     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.02.028     Document Type: Article

References (136)

1. [1] Moch, H., Humphrey, P.A., Ulbright, T.M., Reuter, V., WHO Classification of Tumours of the Urinary System and Male Genital Organs. 2016, International Agency for Research on Cancer, Lyon, France.
2. [2] Kovi, J., Jackson, M.A., Heshmat, M.Y., Ductal spread in prostatic carcinoma. Cancer 56 (1985), 1566–1573.
3. [3] Magers, M., Kunju, L.P., Wu, A., Intraductal carcinoma of the prostate: morphologic features, differential diagnoses, significance, and reporting practices. Arch Pathol Lab Med 139 (2015), 1234–1241.
4. [4] Humphrey, P.A., Intraductal carcinoma of the prostate. J Urol 194 (2015), 1434–1435.
5. [5] McNeal, J.E., Yemoto, C.E., Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. Am J Surg Pathol 20 (1996), 802–814.
6. [6] Tsuzuki, T., Intraductal carcinoma of the prostate: a comprehensive and updated review. Int J Urol 22 (2015), 140–145.
7. [7] Robinson, B., Magi-Galluzzi, C., Zhou, M., Intraductal carcinoma of the prostate. Arch Pathol Lab Med 136 (2012), 418–425.
8. [8] Robinson, B.D., Epstein, J.I., Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings. J Urol 184 (2010), 1328–1333.
9. [9] Watts, K., Li, J., Magi-Galluzzi, C., Zhou, M., Incidence and clinicopathological characteristics of intraductal carcinoma detected in prostate biopsies: a prospective cohort study. Histopathology 63 (2013), 574–579.
10. [10] Miyai, K., Divatia, M.K., Shen, S.S., Miles, B.J., Ayala, A.G., Ro, J.Y., Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between “precursor-like” and “regular type” lesions. Int J Clin Exp Pathol 7 (2014), 2518–2526.
11. [11] Guo, C.C., Epstein, J.I., Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance. Mod Pathol 19 (2006), 1528–1535.
12. [12] Morais, C.L., Han, J.S., Gordetsky, J., et al. Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy. Am J Surg Pathol 39 (2015), 169–178.
13. [13] Epstein, J.I., Zelefsky, M.J., Sjoberg, D.D., et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 69 (2016), 428–435.
14. [14] Humphrey, P.A., Histological variants of prostatic carcinoma and their significance. Histopathology 60 (2012), 59–74.
15. [15] Yaskiv, O., Cao, D., Humphrey, P.A., Microcystic adenocarcinoma of the prostate: a variant of pseudohyperplastic and atrophic patterns. Am J Surg Pathol 34 (2010), 556–561.
16. [16] Parwani, A.V., Herawi, M., Epstein, J.I., Pleomorphic giant cell adenocarcinoma of the prostate: report of 6 cases. Am J Surg Pathol 30 (2006), 1254–1259.
17. [17] Lopez-Beltran, A., Eble, J.N., Bostwick, D.G., Pleomorphic giant cell carcinoma of the prostate. Arch Pathol Lab Med 129 (2005), 683–685.
18. [18] Evans, A.J., Humphrey, P.A., Belani, J., van der Kwast, T.H., Srigley, J.R., Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol 30 (2006), 684–693.
19. [19] Epstein, J.I., Egevad, L., Humphrey, P.A., Montironi, R., Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol 38 (2014), e6–e19.
20. [20] Gelmann, E.P., Bowen, C., Bubendorf, L., Expression of NKX3.1 in normal and malignant tissues. Prostate 55 (2003), 111–117.
21. [21] Gurel, B., Ali, T.Z., Montgomery, E.A., et al. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol 34 (2010), 1097–1105.
22. [22] Sheridan, T., Herawi, M., Epstein, J.I., Illei, P.B., The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Am J Surg Pathol 31 (2007), 1351–1355.
23. [23] Epstein, J.I., Egevad, L., Amin, M.B., Delahunt, B., Srigley, J.R., Humphrey, P.A., The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40 (2016), 244–252.
24. [24] Epstein, J.I., Algaba, F., Allsbrook, W.C. Jr., et al. Acinar adenocarcinoma. Eble, J.N., Sauter, G., Epstein, J.I., Sesterhenn, I.A., (eds.) Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs, 2004, IARC Press, Lyon, France, 162.
25. [25] Kir, G., Sarbay, B.C., Gumus, E., Topal, C.S., The association of the cribriform pattern with outcome for prostatic adenocarcinomas. Pathol Res Pract 210 (2014), 640–644.
26. [26] Dong, F., Yang, P., Wang, C., et al. Architectural heterogeneity and cribriform pattern predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma. Am J Surg Pathol 37 (2013), 1855–1861.
27. [27] Kweldam, C.F., Wildhagen, M.F., Steyerberg, E.W., Bangma, C.H., van der Kwast, T.H., van Leenders, G.J., Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Mod Pathol 28 (2015), 457–464.
28. [28] Morash, C., Tey, R., Agbassi, C., et al. Active surveillance for the management of localized prostate cancer: guideline recommendations. Can Urol Assoc J 9 (2015), 171–178.
29. [29] Stamey, T.A., McNeal, J.E., Yemoto, C.M., Sigal, B.M., Johnstone, I.M., Biological determinants of cancer progression in men with prostate cancer. JAMA 281 (1999), 1395–1400.
30. [30] Cheng, L., Davidson, D.D., Lin, H., Koch, M.O., Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy. Cancer 110 (2007), 1967–1972.
31. [31] Sauter, G., Steurer, S., Clauditz, T.S., et al. Clinical utility of quantitative Gleason grading in prostate biopsies and prostatectomy specimens. Eur Urol 69 (2016), 592–598.
32. [32] Pierorazio, P.M., Walsh, P.C., Partin, A.W., Epstein, J.I., Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 111 (2013), 753–760.
33. [33] Rubin, M.A., Girelli, G., Demichelis, F., Genomic correlates to the newly proposed grading prognostic groups for prostate cancer. Eur Urol 69 (2016), 557–560.
34. [34] Barbieri, C.E., Bangma, C.H., Bjartell, A., et al. The mutational landscape of prostate cancer. Eur Urol 64 (2013), 567–576.
35. [35] Barbieri, C.E., Rubin, M.A., Genomic rearrangements in prostate cancer. Curr Opin Urol 25 (2015), 71–76.
36. [36] Robinson, D., Van Allen, E.M., Wu, Y.M., et al. Integrative clinical genomics of advanced prostate cancer. Cell 161 (2015), 1215–1228.
37. [37] Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163 (2015), 1011–1025.
38. [38] Epstein, J.I., Amin, M.B., Reuter, V.R., Mostofi, F.K., The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22 (1998), 1435–1448.
39. [39] Bircan, S., Candir, O., Serel, T.A., Comparison of WHO 1973, WHO/ISUP 1998, WHO 1999 grade and combined scoring systems in evaluation of bladder carcinoma. Urol Int 73 (2004), 201–208.
40. [40] Busch, C., Algaba, F., The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch 441 (2002), 105–108.
41. [41] Billis, A., Carvalho, R.B., Mattos, A.C., et al. Tumor grade heterogeneity in urothelial bladder carcinoma—proposal of a system using combined numbers. Scand J Urol Nephrol 35 (2001), 275–279.
42. [42] Epstein, J.I., The new World Health Organization/International Society of Urological Pathology (WHO/ISUP) classification for TA, T1 bladder tumors: is it an improvement?. Crit Rev Oncol Hematol 47 (2003), 83–89.
43. [43] Jones, T.D., Cheng, L., Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts. J Urol 175 (2006), 1995–2003.
44. [44] Montironi, R., Lopez-Beltran, A., Mazzucchelli, R., Bostwick, D.G., Classification and grading of the non-invasive urothelial neoplasms: recent advances and controversies. J Clin Pathol 56 (2003), 91–95.
45. [45] Montironi, R., Mazzucchelli, R., Colanzi, P., et al. Improving inter-observer agreement and certainty level in diagnosing and grading papillary urothelial neoplasms: usefulness of a Bayesian belief network. Eur Urol 41 (2002), 449–457.
46. [46] Nishiyama, N., Kitamura, H., Maeda, T., et al. Clinicopathological analysis of patients with non-muscle-invasive bladder cancer: prognostic value and clinical reliability of the 2004 WHO classification system. Jpn J Clin Oncol 43 (2013), 1124–1131.
47. [47] Yin, H., Leong, A.S., Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up. Am J Clin Pathol 121 (2004), 679–687.
48. [48] Amin, M.B., McKenney, J.K., Paner, G.P., et al. ICUD-EAU International Consultation on Bladder Cancer 2012: pathology. Eur Urol 63 (2013), 16–35.
49. [49] Amin, M.B., Smith, S.C., Reuter, V.E., et al. Update for the practicing pathologist: the International Consultation on Urologic Disease-European Association of Urology consultation on bladder cancer. Mod Pathol 28 (2015), 612–630.
50. [50] Amin, M.B., Trpkov, K., Lopez-Beltran, A., Grignon, D., Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol 38 (2014), e20–e34.
51. [51] Eble, J.N., Sauter, G., Epstein, J.I., Sesterhenn, I.A., Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. 2004, IARC Press, Lyon, France.
52. [52] van Rhijn, B.W., Vis, A.N., van der Kwast, T.H., et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 21 (2003), 1912–1921.
53. [53] Chow, N.H., Cairns, P., Eisenberger, C.F., et al. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer 89 (2000), 514–518.
54. [54] Hartmann, A., Moser, K., Kriegmair, M., Hofstetter, A., Hofstaedter, F., Knuechel, R., Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 154 (1999), 721–727.
55. [55] Obermann, E.C., Junker, K., Stoehr, R., et al. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J Pathol 199 (2003), 50–57.
56. [56] Readal, N., Epstein, J.I., Papillary urothelial hyperplasia: relationship to urothelial neoplasms. Pathology. 42 (2010), 360–363.
57. [57] Taylor, D.C., Bhagavan, B.S., Larsen, M.P., Cox, J.A., Epstein, J.I., Papillary urothelial hyperplasia. A precursor to papillary neoplasms. Am J Surg Pathol 20 (1996), 1481–1488.
58. [58] van Oers, J.M., Adam, C., Denzinger, S., et al. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer 119 (2006), 1212–1215.
59. [59] Dalbagni, G., Genega, E., Hashibe, M., et al. Cystectomy for bladder cancer: a contemporary series. J Urol 165 (2001), 1111–1116.
60. [60] Linder, B.J., Frank, I., Cheville, J.C., et al. Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis. J Urol 189 (2013), 1670–1675.
61. [61] Kim, S.P., Frank, I., Cheville, J.C., et al. The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. J Urol 188 (2012), 405–409.
62. [62] Xylinas, E., Rink, M., Robinson, B.D., et al. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer 49 (2013), 1889–1897.
63. [63] Guo, C.C., Gomez, E., Tamboli, P., et al. Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. Hum Pathol 40 (2009), 1448–1452.
64. [64] Ikegami, H., Iwasaki, H., Ohjimi, Y., Takeuchi, T., Ariyoshi, A., Kikuchi, M., Sarcomatoid carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical analysis of 14 patients. Hum Pathol 31 (2000), 332–340.
65. [65] Lagwinski, N., Thomas, A., Stephenson, A.J., et al. Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases. Am J Surg Pathol 31 (2007), 1777–1787.
66. [66] Hansel, D.E., Zhang, Z., Petillo, D., Teh, B.T., Gene profiling suggests a common evolution of bladder cancer subtypes. BMC Med Genomics, 6, 2013, 42.
67. [67] Blochin, E.B., Park, K.J., Tickoo, S.K., Reuter, V.E., Al-Ahmadie, H., Urothelial carcinoma with prominent squamous differentiation in the setting of neurogenic bladder: role of human papillomavirus infection. Mod Pathol 25 (2012), 1534–1542.
68. [68] Schwartz, L.E., Khani, F., Bishop, J.A., Vang, R., Epstein, J.I., Carcinoma of the uterine cervix unvolving the genitourinary tract: a potential diagnostic dilemma. Am J Surg Pathol 40 (2016), 27–35.
69. [69] Choi, W., Czerniak, B., Ochoa, A., et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol 11 (2014), 400–410.
70. [70] Damrauer, J.S., Hoadley, K.A., Chism, D.D., et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 111 (2014), 3110–3115.
71. [71] Grignon, D.J., Ro, J.Y., Ayala, A.G., Johnson, D.E., Ordonez, N.G., Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer 67 (1991), 2165–2172.
72. [72] el-Mekresh, M.M., el-Baz, M.A., Abol-Enein, H., Ghoneim, M.A., Primary adenocarcinoma of the urinary bladder: a report of 185 cases. Br J Urol 82 (1998), 206–212.
73. [73] Zaghloul, M.S., Nouh, A., Nazmy, M., et al. Long-term results of primary adenocarcinoma of the urinary bladder: A report on 192 patients. Urol Oncol 24 (2006), 13–20.
74. [74] Grignon, D.J., Ro, J.Y., Ayala, A.G., Johnson, D.E., Primary signet-ring cell carcinoma of the urinary bladder. Am J Clin Pathol 95 (1991), 13–20.
75. [75] Yamase, H.T., Wurzel, R.S., Nieh, P.T., Gondos, B., Immunohistochemical demonstration of human chorionic gonadotropin in tumors of the urinary bladder. Ann Clin Lab Sci 15 (1985), 414–417.
76. [76] Cox, R., Epstein, J.I., Large nested variant of urothelial carcinoma: 23 cases mimicking von brunn nests and inverted growth pattern of noninvasive papillary urothelial carcinoma. Am J Surg Pathol 35 (2011), 1337–1342.
77. [77] Holmang, S., Johansson, S.L., The nested variant of transitional cell carcinoma—a rare neoplasm with poor prognosis. Scand J Urol Nephrol 35 (2001), 102–105.
78. [78] Drew, P.A., Furman, J., Civantos, F., Murphy, W.M., The nested variant of transitional cell carcinoma: an aggressive neoplasm with innocuous histology. Mod Pathol 9 (1996), 989–994.
79. [79] Lin, O., Cardillo, M., Dalbagni, G., Linkov, I., Hutchinson, B., Reuter, V.E., Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 12 cases. Mod Pathol 16 (2003), 1289–1298.
80. [80] Young, R.H., Eble, J.N., Unusual forms of carcinoma of the urinary bladder. Hum Pathol 22 (1991), 948–965.
81. [81] Young, R.H., Zukerberg, L.R., Microcystic transitional cell carcinomas of the urinary bladder. A report of four cases. Am J Clin Pathol 96 (1991), 635–639.
82. [82] Amin, M.B., Ro, J.Y., el-Sharkawy, T., et al. Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol 18 (1994), 1224–1232.
83. [83] Comperat, E., Roupret, M., Yaxley, J., et al. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology 42 (2010), 650–654.
84. [84] Guo, C.C., Tamboli, P., Czerniak, B., Micropapillary variant of urothelial carcinoma in the upper urinary tract: a clinicopathologic study of 11 cases. Arch Pathol Lab Med 133 (2009), 62–66.
85. [85] Kamat, A.M., Dinney, C.P., Gee, J.R., et al. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110 (2007), 62–67.
86. [86] Sangoi, A.R., Beck, A.H., Amin, M.B., et al. Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol 34 (2010), 1367–1376.
87. [87] Samaratunga, H., Khoo, K., Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study. Histopathology 45 (2004), 55–64.
88. [88] Spaliviero, M., Dalbagni, G., Bochner, B.H., et al. Clinical outcome of patients with T1 micropapillary urothelial carcinoma of the bladder. J Urol 192 (2014), 702–707.
89. [89] Huang, H., Jadallah, S., Chen, Y.B., et al. Her2 expression in urothelial carcinoma with micropapillary morphology: preferential overexpresssion by the micropapillary component. Lab Invest, 93, 2013 219a-a.
90. [90] Ross, J.S., Wang, K., Gay, L.M., et al. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin Cancer Res 20 (2014), 68–75.
91. [91] Schneider, S.A., Sukov, W.R., Frank, I., et al. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. Mod Pathol 27 (2014), 758–764.
92. [92] Kaimakliotis, H.Z., Monn, M.F., Cheng, L., et al. Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes. Urology 83 (2014), 1112–1116.
93. [93] Ricardo-Gonzalez, R.R., Nguyen, M., Gokden, N., Sangoi, A.R., Presti, J.C. Jr., McKenney, J.K., Plasmacytoid carcinoma of the bladder: a urothelial carcinoma variant with a predilection for intraperitoneal spread. J Urol 187 (2012), 852–855.
94. [94] Ro, J.Y., Shen, S.S., Lee, H.I., et al. Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases. Am J Surg Pathol 32 (2008), 752–757.
95. [95] Dayyani, F., Czerniak, B.A., Sircar, K., et al. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol 189 (2013), 1656–1661.
96. [96] Gonzalez-Roibon, N.D., Chaux, A., Al-Hussain, T., et al. Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder. Hum Pathol 44 (2013), 612–622.
97. [97] Al-Ahmadie, H., Iyer, G., Mehra, R., et al. E-cadherin (CDH1) is frequently mutated in urothelial carcinoma with signet-ring cell and plasmacytoid morphology. Mod Pathol, 26, 2013 191A-A.
98. [98] Nigwekar, P., Tamboli, P., Amin, M.B., Osunkoya, A.O., Ben-Dor, D., Plasmacytoid urothelial carcinoma: detailed analysis of morphology with clinicopathologic correlation in 17 cases. Am J Surg Pathol 33 (2009), 417–424.
99. [99] Oliva, E., Amin, M.B., Jimenez, R., Young, R.H., Clear cell carcinoma of the urinary bladder: a report and comparison of four tumors of mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems. Am J Surg Pathol 26 (2002), 190–197.
100. [100] Drew, P.A., Murphy, W.M., Civantos, F., Speights, V.O., The histogenesis of clear cell adenocarcinoma of the lower urinary tract. Case series and review of the literature. Hum Pathol 27 (1996), 248–252.
101. [101] Lah, K., Desai, D., Hadway, P., Perry-Keene, J., Coughlin, G., Primary vesical clear cell adenocarcinoma arising in endometriosis: a rare case of mullerian origin. Anticancer Res 33 (2013), 615–617.
102. [102] Young, R.H., Scully, R.E., Clear cell adenocarcinoma of the bladder and urethra. A report of three cases and review of the literature. Am J Surg Pathol 9 (1985), 816–826.
103. [103] Mai, K.T., Yazdi, H.M., Perkins, D.G., Morash, C., Green, J., Multicentric clear cell adenocarcinoma in the urinary bladder and the urethral diverticulum: evidence of origin of clear cell adenocarcinoma of the female lower urinary tract from Mullerian duct remnants. Histopathology 36 (2000), 380–382.
104. [104] Idrees, M.T., Alexander, R.E., Kum, J.B., Cheng, L., The spectrum of histopathologic findings in vesical diverticulum: implications for pathogenesis and staging. Hum Pathol 44 (2013), 1223–1232.
105. [105] Kong, M.X., Zhao, X., Kheterpal, E., et al. Histopathologic and clinical features of vesical diverticula. Urology 82 (2013), 142–147.
106. [106] Walker, N.F., Gan, C., Olsburgh, J., Khan, M.S., Diagnosis and management of intradiverticular bladder tumours. Nat Rev Urol 11 (2014), 383–390.
107. [107] Hoglund, M., On the origin of syn- and metachronous urothelial carcinomas. Eur Urol 51 (2007), 1185–1193 discussion 1193.
108. [108] Nordentoft, I., Lamy, P., Birkenkamp-Demtroder, K., et al. Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep 7 (2014), 1649–1663.
109. [109] van Tilborg, A.A., de Vries, A., de Bont, M., Groenfeld, L.E., van der Kwast, T.H., Zwarthoff, E.C., Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet 9 (2000), 2973–2980.
110. [110] Brandli, D.W., Ulbright, T.M., Foster, R.S., et al. Stroma adjacent to metastatic mature teratoma after chemotherapy for testicular germ cell tumors is derived from the same progenitor cells as the teratoma. Cancer Res 63 (2003), 6063–6068.
111. [111] Knowles, M.A., Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis 27 (2006), 361–373.
112. [112] Allory, Y., Beukers, W., Sagrera, A., et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 65 (2014), 360–366.
113. [113] Gunes, C., Rudolph, K.L., The role of telomeres in stem cells and cancer. Cell 152 (2013), 390–393.
114. [114] Groll, R.J., Warde, P., Jewett, M.A., A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol 64 (2007), 182–197.
115. [115] Balbas-Martinez, C., Sagrera, A., Carrillo-de-Santa-Pau, E., et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet 45 (2013), 1464–1469.
116. [116] Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507 (2014), 315–322.
117. [117] Guo, G., Sun, X., Chen, C., et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 45 (2013), 1459–1463.
118. [118] Kandoth, C., McLellan, M.D., Vandin, F., et al. Mutational landscape and significance across 12 major cancer types. Nature 502 (2013), 333–339.
119. [119] Slade, I., Bacchelli, C., Davies, H., et al. DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J Med Genet 48 (2011), 273–278.
120. [120] Fahmy, M., Mansure, J.J., Brimo, F., et al. Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer. Hum Pathol 44 (2013), 1766–1772.
121. [121] Chaux, A., Comperat, E., Varinot, J., et al. High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pT1 urothelial carcinoma of the bladder: a tissue microarray study of 156 patients treated by transurethral resection. Urology 81 (2013), 116–122.
122. [122] Inman, B.A., Sebo, T.J., Frigola, X., et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109 (2007), 1499–1505.
123. [123] Powles, T., Eder, J.P., Fine, G.D., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 (2014), 558–562.
124. [124] Fedorov, O., Lingard, H., Wells, C., et al. [1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains. J Med Chem 57 (2014), 462–476.
125. [125] Filippakopoulos, P., Qi, J., Picaud, S., et al. Selective inhibition of BET bromodomains. Nature 468 (2010), 1067–1073.
126. [126] Hay, D.A., Fedorov, O., Martin, S., et al. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc 136 (2014), 9308–9319.
127. [127] van Rhijn, B.W., van der Kwast, T.H., Liu, L., et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol 187 (2012), 310–314.
128. [128] Gui, Y., Guo, G., Huang, Y., et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 43 (2011), 875–878.
129. [129] Iyer, G., Al-Ahmadie, H., Schultz, N., et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 31 (2013), 3133–3140.
130. [130] Kim, P.H., Cha, E.K., Sfakianos, J.P., et al. Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder. Eur Urol 67 (2015), 198–201.
131. [131] Birkhahn, M., Mitra, A.P., Williams, A.J., et al. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol 57 (2010), 12–20.
132. [132] Lindgren, D., Frigyesi, A., Gudjonsson, S., et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 70 (2010), 3463–3472.
133. [133] Netto, G.J., Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?. Nat Rev Urol 9 (2012), 41–51.
134. [134] Sanchez-Carbayo, M., Socci, N.D., Lozano, J., Saint, F., Cordon-Cardo, C., Defining Molecular Profiles of Poor Outcome in Patients With Invasive Bladder Cancer Using Oligonucleotide Microarrays. J Clin Oncol 24 (2006), 778–789.
135. [135] Shariat, S.F., Ashfaq, R., Sagalowsky, A.I., Lotan, Y., Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 177 (2007), 481–487 discussion 487.
136. [136] van der Kwast, T.H., Bapat, B., Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling. Curr Opin Urol 19 (2009), 516–521.